Evaluation of sample size and power for multi-arm survival trails allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over

Statistics in Medicine

Volumn 25, Issue 15, 2006, Pages 2521-2542

  Barthel, Friederike M S ^a   Babiker, A ^a   Royston, P ^a   Parmar, M K B ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Clinical Trials; Power; Sample size; Survival analysis

Indexed keywords

ARTICLE; BIOSTATISTICS; CALCULATION; CLINICAL RESEARCH; CLINICAL STUDY; COMPUTER PROGRAM; FOLLOW UP; LOG RANK TEST; METHODOLOGY; OUTCOME ASSESSMENT; POWER ANALYSIS; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE; SIMULATION; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; SURVIVAL; VALIDATION PROCESS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTER SIMULATION; HIV INFECTIONS; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SOFTWARE;

EID: 33746153141     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2517     Document Type: Article

References (31)

1. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981; 68(1):316-319.
2. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine 1982; 1(2):121-129.
3. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983; 39(2): 499-503.
4. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986; 42(3): 507-519.
5. Yateman NA, Skene AM. Sample sizes for proportional hazards survival studies with arbitrary patient entry and loss to follow-up distributions. Statistics in Medicine 1992; 11(8):1103-1113.
6. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 1988; 44(1): 229-241.
7. Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Controlled Clinical Trials 1995; 16(6):395-407.
8. Makuch RW, Simon RM. Sample size requirements of comparing time-to-failure among k treatment groups. Journal of Chronic Diseases 1982; 35(11):861-867.
9. Ahnn S, Anderson SJ. Sample size determination in complex clinical trials comparing more than two groups for survival endpoints. Statistics in Medicine 1998; 17(21):2525-2534.
10. Halabi S, Singh B. Sample size determination for comparing several survival curves with unequal allocations. Statistics in Medicine 2004; 23:1793-1815.
11. Tarone RE, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977; 64(1): 156-160.
12. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982; 69(3):553-566.
13. Cox D. Regression models and life tables (with discussion). Journal of the Royal Statistical Society, Series B 1972; 34(2):187-220.
14. Haynam G, Govindarajulu Z, Leone F. Tables of the cumulative non-central chi-square distribution. Case Statistical Laboratory, Publication No. 104, 1962.
15. Ahnn S, Anderson SJ. Sample size determination for comparing more than two survival distributions. Statistics in Medicine 1995; 14(20):2273-2282.
16. Cox DR, Oakes D. Analysis of Survival Data. Monographs on Statistics and Applied Probability. Chapman & Hall: London, 1984.
17. Royston P, Babiker A. A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome. The Stata Journal 2002; 2(2):151-163.
18. Barthel F, Royston P, Babiker A. A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: update. The Stata Journal 2005; 5(1):123-129.
19. Medical Research Council. A Randomised Trial of Two vs Fire CT Scans in the Surveillance of Patients with Stage I Teratoma of the Testis. Clinical Protocol, MRC Clinical Trials Unit, London, 1997.
20. Medical Research Council and EORTC. Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma. Clinical Protocol, MRC Clinical Trials Unit, London, 1996.
21. Medical Research Council. A Randomised Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer. Clinical Protocol, MRC Clinical Trials Unit, London, 2003.
22. Medical Research Council. CHARTWEL vs Conventional Radiotherapy in Post Operative Head and Neck Cancer Patients. Clinical Protocol, MRC Clinical Trials Unit, London, 2000.
23. Rubinstein L, Gail M, Santner T. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. Journal of Chronic Disease 1981; 34(9):469-479.
24. Self S, Mauritsen R, Ohara J. Power calculations of likelihood ratio tests in generalized linear models. Biometrics 1992; 48(1):31-39.
25. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38(1):163-170.
26. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Controlled Clinical Trials 1986; 7(3):189-199.
27. Sankoh A, Huque M, Dubey S. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Statistics in Medicine 1997; 16(22):2529-2542.
28. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes, with an application in ovarian cancer. Statistics in Medicine 2003; 22(14):2239-2256.
29. Gnedenko B, Kolmogorov A. Limit Distributions for Sums of Independent Random Variables. Addison-Wesley: Reading, MA, 1954.
30. Searle S. Matrix Algebra Useful for Statistics. Wiley: New York, 1982.
31. Evans M, Hastings N, Peacock B. Statistical Distributions (3rd edn). Wiley Interscience: New York, 2000.